RT Book, Section A1 Zeichner, Joshua A1 Mitchell, Krystal A2 Baumann, Leslie S. A2 Rieder, Evan A. A2 Sun, Mary D. SR Print(0) ID 1190668594 T1 Rosacea T2 Baumann’s Cosmetic Dermatology, 3e YR 2022 FD 2022 PB McGraw Hill LLC PP New York, NY SN 9780071794190 LK dermatology.mhmedical.com/content.aspx?aid=1190668594 RD 2024/03/28 AB SUMMARY POINTSWhat’s newThe potential role of probiotics in rosacea given the innate/adaptive immunity dysregulation and the contribution of commensal and pathogenic bacteria.Transient receptor potential channels, vanilloid (TRPV) and ankyrin (TRPA), may contribute to the role of flushing and burning in rosacea.Zonulin, a human protein that regulates intestinal permeability, is significantly higher in patients with rosacea.Topical minocycline foam (Zilxi) has recently received FDA approval for the treatment of rosacea.What’s importantTreatment of rosacea focuses on patient education, skincare, and pharmacologic/procedural interventions.Distinguishing rosacea from other conditions and initiation of early treatment when a patient reports flushing and burning.Treatment of rosacea involves addressing both background facial redness and inflammatory lesions.What We Don’t KnowThe pathogenesis of rosacea has yet to be fully elucidated and it is unclear whether the four rosacea subtypes are truly variants of the same condition.The mechanism by which TLR2 is activated by Demodex mites.The potential virulence factors of S. epidermidis in patients with rosacea.What’s comingThe use of cromolyn, a mast cell stabilizer, in patients with rosacea.The use of protease serine inhibitors to prevent the formation of the abnormal cathelicidin (LL-37) in patients with rosacea.